Remoxipride
From Wikipedia, the free encyclopedia
 |
|
|
Remoxipride
|
|
| Systematic (IUPAC) name | |
| 3-Bromo-N-[ [(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxy-benzamide | |
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| Chemical data | |
| Formula | ? |
| Mol. mass | 371.27 g/mol |
| Pharmacokinetic data | |
| Bioavailability | C16H23BrN2O3 |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Remoxipride is a substituted benzamide which was a promising antipsychotic during clinical trials in the 1990s, but was removed due to possible side effects.
[edit] Clinical trials
Remoxipride is a selective D2 antagonist, with a relatively low effective dosage and low incidence of side effects relative to haloperidol. However, after its introduction in Europe, its use was correlated with incidence of aplastic anemia in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
